Randomized trial: First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma
25 Jan, 2021 | 01:13h | UTCFirst-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial – The Lancet (link to abstract – $ for full-text)